A Phase II Study of Stereotactic Ablative Radiotherapy for Low- and Intermediate-Risk Prostate Cancer Using an Injectable Rectal Spacer

Full Title

Phase II Study of Stereotactic Ablative Radiotherapy (SABR) for Low/Intermediate Risk Prostate Cancer with Injectable Rectal Spacer


One of the side effects of radiation therapy for prostate cancer is rectal irritation. In this study, researchers are evaluating the use of a gel disc that is injected into the space between the prostate and the rectum. The spacer is designed to protect the rectum from the direct effects of high-dose radiation. Researchers will see if the rectal spacer reduces the rate of rectal ulceration in men with localized prostate cancer receiving stereotactic ablative radiotherapy.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have low-risk or intermediate-risk prostate cancer that has not yet been treated.
  • Patients may not be scheduled for additional treatment after the study.
  • This study is for men ages 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Michael Zelefsky at 212-639-6802.





Disease Status

Newly Diagnosed